AstraZeneca Holds Talks with Bristol Myers Squibb on $400 Billion Merger AstraZeneca is in discussions with Bristol Myers Squibb about a potential merger worth approximately $400 billion, creating one of the largest pharmaceutical companies worldwide.
The proposed deal would surpass even industry giants like Pfizer and Merck. The talks have sparked concern among investors and analysts, who are trying to understand the motivations behind AstraZeneca's move.
Some speculate that the company is seeking to strengthen its market position, while others believe it may be a desperate attempt to boost its sagging stock price after recent declines.